MedTrace Logo

Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric Cancer

NCT05348161 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-04-27

No results posted yet for this study

Summary

Dynamic multiomics explore the efficacy and mechanism of anti-HER2 \& immunotherapy of HER2 Positive GC

Conditions

  • HER2 Positive Advanced Gastric Cancer

Interventions

PROCEDURE

Samples including blood and tissue collection

Tissue and peripheral blood sample of 100 gastric cancer patients will be collected at the baseline and time point response of therapy.

PROCEDURE

CTC detection

Peripheral blood collected from patients will be administrated to CTC detection.

PROCEDURE

ctDNA detection

DNA extraction from patients' peripheral blood will be measured by 741 panel DNA sequence.

PROCEDURE

10×genomics single cell RNA sequence

Tissue collected from patients will be digested into single cell suspension and administrated to 10×genomics single cell RNA sequence.

PROCEDURE

Whole exon sequence

DNA will be extracted from patients' tissue and administrated to whole exon sequence.

PROCEDURE

Proteomics detection

Peripheral blood collected from patients will be administrated to proximity extension assay .

Sponsors & Collaborators

  • Peking University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2023-01-01
Completion
2025-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05348161 on ClinicalTrials.gov